Collecting stem cells from healthy unrelated donors using filgrastim
Official title: Filgrastim-Mobilized Peripheral Blood Stem Cells for Allogeneic Transplantation With Unrelated Donors
Run by Center for International Blood and Marrow Transplant Research · NCT00785525 · Data updated 2026-11-12
This study is testing a way to safely collect stem cells from healthy volunteers using a medication called filgrastim to see if it can help make more stem cells available for people needing transplants.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 60 Years |
| Sex | All |
| Enrollment | 60000 (estimated) |
| Sponsor | Center for International Blood and Marrow Transplant Research Research network |
| Locations | 4 sites (Boca Raton, Florida and 3 other locations) |
| Status | Recruiting |
| Started | February 1997 |
| Main results expected | January 2030 |
| Study ends | January 2030 |
| Registry record updated | April 13, 2025 |
| Trial ID | NCT00785525 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are healthy individuals who are willing to donate stem cells and meet the eligibility criteria set by the National Marrow Donor Program.
✕Probably not a fit
Patients who are pregnant, breastfeeding, or have certain medical histories such as autoimmune disorders or previous thromboembolic events may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to establish a system for collecting filgrastim-mobilized peripheral blood stem cells (PBSC) from unrelated donors registered with the National Marrow Donor Program. It evaluates the safety of filgrastim administration and the leukapheresis process among these donors, as well as the safety and efficacy of the collected PBSC in transplant recipients. The study also seeks to determine how acceptable the donation process is for healthy individuals. By leveraging a large donor registry, the study hopes to enhance the availability of stem cells for transplantation.
Why it matters
Potential benefit: If successful, this study could improve the safety and efficacy of stem cell transplants from unrelated donors, potentially saving more lives.
How similar studies have gone: Previous studies have shown success in using filgrastim for mobilizing stem cells, making this approach well-supported by existing evidence.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. PBSC donors must meet the same criteria as NMDP marrow donors. These criteria are set forth in the Donor Center Manual of Operations. 2. Confirmatory pregnancy test must be performed within 15 days of collection and prior to the start of filgrastim administration; this may require more than one test to be performed. Exclusion Criteria: 1. Pregnancy or uninterruptible breastfeeding. Pregnancy is an absolute contraindication under this protocol. Women who are breastfeeding must be willing and able to interrupt breastfeeding during the administration of filgrastim and for two days following the final dose. 2. Sensitivity to filgrastim or to E. coli-derived recombinant protein products. 3. History of autoimmune disorders, including rheumatic diseases and thyroid disorders. Exception: As with bone marrow donations, donors with a history of thyroid disease who have undergone successful therapy may be suitable. 4. History of deep vein thrombosis or pulmonary embolism. 5. History of iritis or episcleritis. 6. Thrombocytopenia \< 150 x 10\^9/L (\< 150,000/uL) at baseline evaluation. 7. Current treatment with lithium. Drug interactions between filgrastim and lithium, which may potentiate the release of neutrophils, have not been fully evaluated. 8. Positive Hemoglobin-Solubility (e.g., SickleDex or equivalent) test. 9. Donors receiving experimental therapy or investigational agents. 10. Positive pregnancy test collected/reported prior to start of filgrastim.
Where it's running
-
Gift of Life Bone Marrow Foundation
Boca Raton, Florida, United States Recruiting -
C.W. Bill Young Marrow Donor Center
Rockville, Maryland, United States Recruiting -
Be The Match
Minneapolis, Minnesota, United States Recruiting -
DKMS Americas
New York, New York, United States Recruiting
Study contacts
- Principal investigator: John P Miller, MD, PhD — National Marrow Donor Program
- Study coordinator: Lisa Erickson
- Email: PBSCStudyTeam@nmdp.org
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Do Quercefit® or Ubiqsome™ help with aging and metabolic health in adults 50–75?
This study tests whether Quercefit® or Ubiqsome™ can improve aging markers, blood sugar, and heart health in sedentary adults aged 50–75 compared with a placebo.
-
NVTIA Ergothioneine for Healthy Aging and Skin Health
This study tests whether taking NVTIA Ergothioneine daily for 12 weeks helps healthy adults age more gracefully and keeps skin looking and feeling better compared with a placebo.
-
Miricell supplementation and markers of healthy aging
This trial tests whether taking Miricell once daily for 12 weeks improves cellular health and brain/metabolic indicators in adults aged 40–70 compared with a placebo.
-
Does daily lean beef support brain health in older adults
In healthy adults aged 65 and up, this study tests whether eating lean beef every day for two weeks can influence brain health markers compared with a non-beef, protein-matched option.
-
Adaptive computerized training to boost thinking in healthy seniors and those with mild cognitive impairment
This study tests whether a computer-based training program can improve executive thinking in older adults, including those with mild cognitive impairment, and see if it also helps memory and well-being.
-
SHARP: Personalized Health and Behavior Plan to Lower Biological Age in Older Adults
A 12-month randomized trial tests whether a personalized health and behavior program can lower biological age and improve function in healthy adults over 50.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.